Post on 14-Jun-2015
description
Strategy for Open Innovation in Sigma Life Science
• Rebecca Poon, PhD, MBA• Business Development Manager
• NCET2 Webinar• Making the Most of U-I Collaborations
• 314-286-7859• rebecca.poon@sial.com
The Strength of Sigma-Aldrich
• Leading supplier in the life science research
market
• Known for quality, reliability, consistency
• World-leading customer & technical service
• Manufacture over 46,000 products
• 1,000,000 customers
• 7,900 employees
• 2008 Sales: $2.2B
• 34 years of continuous growth (Sales & EPS)
Sigma-Aldrich Portfolio
Products – 130,000Number of products
30,000
ChemicalsEquipment items
100,000 (46,000
manufactured)
Large Product Breadth
Pharmaceutical, Diagnostics, Biotechnology CompaniesChemical & Allied Industrial Companies
Customers – 88,000 accounts
Universities, Government, Not-for-Profit OrganizationsHospitals & Commercial Laboratories
35%26%
8%
31%
Broad Customer Base
World Class Distribution & Logistics
Service is key
• Sell into 160 countries from locations in 38 countries• 38 production sites in 10 countries• Over 15,000 orders received & shipped daily• Global distribution network
Sigma-Aldrich Brands
Creating Differentiation Through Innovation: 2009 - 2011
• Accelerate
• Build on Successes
• Focus on Research Biotech
• Expand in Faster Growing Geographies
• Elevate
• Enable Web Strategies: Your Favorite Gene (2009 CIO 100 winner)
• Refine Selection & Integration of New Technologies
• Innovate
• New Ventures Group
• SAGE™ Lab
($824M)
($421M)
($332M)
($624M)
Research BiotechCustomers: Life ScientistsDriving Force: Innovation
Business Units and Revenues
38%
15%
28%
19%
Research Specialities Researach Biotech SAFC Research Essentials
Sigma Life Science Vision
To be a leading destination for life science researchers to access biologically rich information, market leading products and services to help answer their biological
questions
Lead with Breakthrough Products Supported by Rich Biological Information
Sigma Life Science’s Practice in Open Innovation
• Patent Licenses, Option licenses, Cross-Licenses (Many)
• Research Collaborations:
• Odyssey Program: UVA, NIH, U Chicago, Wash U
• Others: Mayo clinic, UNC, UCSD, Fred Hutchinson, U Pittsburgh, UCSF, Columbia
• Joint Grant Application (Boston U, Framingham Heart Study, SABre-CVD)
• Co-development Agreements
• Equity Investment
• M&A for Capabilities and Capacity
• Alliance with Venture Firms (Prolog Ventures)
• Outreach to Consortia (e.g. Protein Quantitation Consortium, Biomarkers, Nanotechnology)
• Consultancy / Scientific Advisory Boards (e.g. Stem Cell, Regulatory ncRNA)
• University Technology Subscription Program (WARF)
Business Development Statistics & Philosophy
• Active Licenses: 490• Oldest Dated: 1983 • No of New Licenses (2007): 28• Total License Related Payments (2008): $12.13 M• Product Royalties (2008): $3.4M
Equitable risk sharing: • Reward on performance• Milestone payments linked to realized technical and market performance• Royalties based on sales revenue, fixed or tiered
Flexibility to meet partners’ different interests:• Options• Carve-outs of IP rights, freedom–to-operate, markets / fields of application
Case Study 1
TRC -- The Broad Institute
• 11 world-renowned academic and
international life sciences companies
• Exclusive license & partnership in
functional validation
• shRNA library: TRCII – 300,000
clones
• Lentivirus particles
• Plasmids
• Bacterial glycerol stock
Case Study 2
Human Proteome Resource (HPR)
• Royal Institute of Technology (KTH),
Stockholm, The Rudbeck Laboratory, and
Uppsala University, Sweden
• Goal: min. one antibody tool to each of
22,000 unique human proteins by 2015
• Exclusive license with Atlas Antibodies
• Added over 6,000 antibodies
• Most highly characterized, monospecific
• Supported by IHC image data (on tissue
microarrays) in Human Protein Atlas (HPA)
Case Study 3
Sangamo Biosciences, Inc.
• Large portfolio of enabling technologies
aggregated from many institutions
• Zinc Finger Nuclease License 2007
• CompoZr™ (www.compozrzfn.com/)
• Milestone reached 1 year early (Jan 09)
• SAGE™ Lab: 12 members, new facility (Aug 21,
09)
• SAGEspeed™ (www.sageresearchmodels.com)
• Michael J Fox Foundation Award Parkinson
Disease Models (Oct 1, 09)
Continuing Outreach Activities
• Campus visits to Office of Technology Licensing
• Sigma Partnering Event (hosted by a local organization)
• Sigma Inventor’s Forum (Webinar)
• Networking through UIDP (University-Industry Demonstration Partnership)
• Participation in AUTM, LES, BIO conferences
• Response to RFPs and fedbizopps.gov
Strategic Areas in Technology Scouting
Technology Areas• Biomolecules
• Functional Genomics
• Cell Based Assays
• Protein Assays
• Transgenics
Research Areas• Stem Cell Biology
• Epigenetics
• Regenerative Medicine
• Oncology
• Neuroscience
• Cell Signaling
• Inflammation
Continuously Expand Technology Portfolio to further basic research and the understanding of biology
•Rebecca Poon, PhD, MBA•Business Development Manager•314-286-7859•rebecca.poon@sial.com